BioHarvest Sciences Earnings Call Transcripts
Fiscal Year 2025
-
Q4 and full-year revenues grew 25% and 37% year-over-year, with gross margins improving to 58–59%. The D2C business, led by VINIA, achieved US category leadership, while the CDMO division advanced four major programs and expects to double or triple revenue in 2026.
-
Q3 2025 revenue grew 39% year-over-year to $9.1M, driven by core products and surging CDMO services. Gross margin improved to 61%, and recent $30.8M in financing fully funds expansion, including new product launches and manufacturing scale-up.
-
A major breakthrough enables scalable production of plant exosomes with unique bioactive compounds, opening new revenue streams in cosmetics, pharma, and nutraceuticals. Commercialization is underway, with direct-to-consumer, B2B, and CDMO opportunities, and a new hydration product launch and HealthPros affiliate system driving growth.
-
A leading plant cell biology innovator detailed its dual business model, highlighting strong growth in direct-to-consumer health products and rapid expansion of its high-margin CDMO partnerships. The company projects further margin gains and positive EBITDA by year-end.
-
Q2 2025 revenue rose 41% to $8.5M with gross margin expanding to 60%. New product launches, Health Pros channel, and CDMO pipeline growth position the company for adjusted EBITDA breakeven in Q4 2025 and further margin gains, despite tariff headwinds.
-
Revenue rose 47% year-over-year to $7.9M, with gross margin up to 58.5% and net loss narrowing to $2.3M. Growth was driven by VINIA product expansion and CDMO partnerships, with profitability targeted in H2 2025. New product launches and major CDMO deals are expected to accelerate growth.
Fiscal Year 2024
-
Achieved 99% revenue growth in 2024, driven by Vinia and new product launches, with Q4 revenue up 62% year-over-year and gross margin reaching 57%. CDMO contracts and manufacturing scale-up support continued high growth, with adjusted EBITDA profitability targeted for the second half of 2025.
-
Q3 2024 revenue doubled year-over-year to $6.5M, driven by strong VINIA sales and subscriber growth, with gross margin up to 57%. CDMO services gained traction with two signed customers and a robust pipeline, while new product launches and margin optimization set the stage for continued growth and profitability in 2025.